ArticleMicroorganisms2023
Development and Validation of a Highly Sensitive Multiplex Immunoassay for SARS-CoV-2 Humoral Response Monitorization: A Study of the Antibody Response in COVID-19 Patients with Different Clinical Profiles during the First and Second Waves in Cadiz, Spain.
Lucia Olvera-Collantes, Noelia Moares, Ricardo Fernandez-Cisnal, Juan P Muñoz-Miranda, Pablo Gonzalez-Garcia, Antonio Gabucio, Carolina Freyre-Carrillo, Juan de Dios Jordan-Chaves, Teresa Trujillo-Soto, Maria P Rodriguez-Martinez and 5 more
Abstract read
In one paragraphArticle in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Lucia Olvera-CollantesDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0002-6980-8871 Noelia MoaresDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0003-0533-4010 Ricardo Fernandez-CisnalDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0001-5307-8539 Juan P Muñoz-MirandaDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.
Antonio GabucioDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0001-6000-9937 Carolina Freyre-CarrilloMicrobiology Service, Puerto Real University Hospital, 11510 Puerto Real, Spain.
Juan de Dios Jordan-ChavesMicrobiology Service, Puerto Real University Hospital, 11510 Puerto Real, Spain.
Teresa Trujillo-SotoMicrobiology Service, Puerta del Mar University Hospital, 11009 Cadiz, Spain.
Maria I Martin-RubioJerez Costa Noroeste Health District, 11403 Jerez de la Frontera, Spain.
Eva EscuerJerez University Hospital, 11407 Jerez de la Frontera, Spain.
Manuel Rodriguez-IglesiasDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0002-7097-9651 Cecilia Fernandez-PonceDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0002-0027-1703 Francisco Garcia-CozarDepartment of Biomedicine, Biotechnology and Public Health, School of Medicine, University of Cadiz, 11003 Cadiz, Spain.ORCID 0000-0003-3720-259X Funding
Consejería de Salud y Familias, Junta de Andalucía, Spain. PECART-0096-2020Institute of Health "Carlos III" from the Spanish Ministry of Science and Innovation COV20-00173
6 · The paper itselfAbstract
There is still a long way ahead regarding the COVID-19 pandemic, since emerging waves remain a daunting challenge to the healthcare system. For this reason, the development of new preventive tools and therapeutic strategies to deal with the disease have been necessary, among which serological assays have played a key role in the control of COVID-19 outbreaks and vaccine development. Here, we have developed and evaluated an immunoassay capable of simultaneously detecting multiple IgG antibodies against different SARS-CoV-2 antigens through the use of Bio-Plex
Indexed as
antibody responseCOVID-19IgG antibodiesmonitoring toolmultiplex immunoassaySARS-CoV-2
Identifiers
PMID38138141
PMCPMC10746014
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390